Day 1 - Thursday 23rd May 2024

10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe

Trends and Strategies to Optimise Value and Patient Access

Hilton London Kensington, London, UK

MARKET ACCESS TRENDS & STRATEGIES

  • Trends that will continue to impact, Market Access, Pricing and Reimbursement in healthcare
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Future trends and developments in the healthcare distribution

Panelist: 

Esther Nzenza, Founder and CEO, Decisive Consulting Ltd.

 

  • The growing importance of market access in all aspects of drug development lifecycle.
  • What affects drug pricing and reimbursement decisions?
  • Impact of evolving legislative landscapes
  • Market access trends and transformative changes in market access strategies

Shaun Rowark, Associate Director for Data Access and Analysis, NICE

  • The ongoing revision of the EU general pharmaceutical legislation will have consequences on the healthcare sector for the next decades. The Commission’s proposal aims to improve access, availability and affordability of medicines, while keeping the EU competitive and attractive for innovation.

Stefano Romanelli, Senior Government Affairs, EUCOPE

Matthias Heck, Sr Director, International TA Policy Strategy, Alexion Pharmaceuticals

  • When and how to integrate value planning into development
  • Staying responsive to changing market conditions
  • Trends to watch
  • Enabling diverse perspectives through timely engagement

Esther Nzenza, Founder and CEO, Decisive Consulting Ltd.

  • Historical use, and impact, of value-based pricing in multi-indication drugs and combination drugs
  • Lessons to be learnt from historical VBP cases
  • Potential avenues to improve on value-based pricing of ‘special’ drug categories
  • Examples of how health systems are adapting their pricing mechanisms

Higia Vassoler, Associate Director – Pricing & Market Access, Red Nucleus

  • This talk will shed light on how internal decisions on price types and managed entry agreements can drive the profitability of the business, and how to avoid blind spots for profitability.
  • How external factors influence the choice of Price Governance will be discussed
  • Examples of the actual decision-making process and the underlying key rationale towards Recordati Rare Diseases’ Price Governance model.

Fabian Schmidt, Global Head, Market Access, HEOR & Policy, Recordati Rare Diseases

REAL-WORLD EVIDENCE

  • Challenges and obstacles in bringing this highly complex therapies to market
  • Stakeholder collaboration on the road towards a solution
  • Lessons learned and applications for new entrants
  • Strategies that can be taken to improve timely market access and access for patients

Ryotaro Ishikawa, Market Access Head Gene Therapies, Novartis Gene Therapies

  • New landscape for risk-sharing agreements among manufacturer, payer and patients
  • Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
  • What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?

Robert Mitchell-Thain, CEO, PBC Foundation

  • Review use of RWD to guide pipeline and portfolio strategy
  • Considerations when using RWD to inform internal decisions
  • The growing use of data tokenization and advanced analytical techniques based on artificial intelligence in RWE
  • The importance of data quality and methodological transparency in RWE.
  • How is RWD and RWE bringing innovation to patients and gaining approval
  • Importance of RWD in transforming clinical research and clinical trial design
  • Experiences to date and identify practical and technological considerations to further implement real-world clinical research
  • The use of RWD early in the process to boost trial diversity and inclusion
  • Challenge in setting diversity goals early in clinical trial planning
  • Development of a diversity plan to ensure adequate representation of racial and ethnic subgroups in clinical trials
  • Utilizing RWE in the post-marketing setting to complement clinical trial findings and support post marketing requirements or commitments for safety and efficacy data in a diverse patient population

Riad Dirani, VP of Global HEOR, Medical Operations & Excellence, Teva

 

  • Why is RWE increasingly being recognised and acknowledged as an evolution in product research and development.
  • How does RWE help regulators, pharmaceutical companies and clinicians better identify trends and patterns in patient outcomes
  • How can you make sure that only quality, reliable and relevant information are collected?
  • How is it use to reduce risk and increase safety?
  • Its use in supporting a robust post market surveillance and accelerating products to market

Moderator: 

Matthias Heck, Sr Director, International TA Policy Strategy, Alexion Pharmaceuticals 

Day 2 Agenda
Scroll to Top